Common clinical plans

Following your appointment in the menopause and PMS clinic, an individualised treatment plan will have been agreed in your clinical summary shared with your GP. Common clinical treatment plans with signposts to useful resources are available here.

On this page

Investigations

Serum estradiol (E2), luteinising hormone (LH), follicle stimulating hormone (FSH) Blood test for diagnosis and assess treatment
Anti-Müllerian hormone (AMH) Blood test to assess fertility
Genetics testing (in POI) To identify potential cause of POI
  • Blood test instructions

    • This blood test must be carried out at Chelsea and Westminster Hospital (CWH) or West Middlesex University Hospital (WMH).
    • You will either receive a paper blood test request form by post or be asked to collect it from Gynaecology Outpatients.
    • You must take the paper request form with you and give it to the phlebotomist when your blood is taken.
    • The sample cannot be processed without this request form.
    • Your sample will be sent to an external laboratory for specialist analysis.
    • Results can take up to four months to become available.
DEXA bone density scan (BMD) X-ray of spine and hip to assess risk of osteoporosis
Transvaginal ultrasound scan (TVUSS) To assess the womb (uterus), womb lining (endometrium) and ovaries

An antra follicle count (AFC) may be requested if assessing fertility

The AFC is the number of small immature follicles seen within the ovary
Dietary calcium check Online self-assessment

Calcium supplements are not generally recommended if you have a calcium rich diet

Excess calcium intake can lead to deposits around the heart and in breast tissue, potentially increasing long-term health risk

Resources

Premature ovarian insufficiency (POI)

POI is a diagnosis made in women under the age of 40. Due to the loss of estrogen, hormone replacement may be advised for symptom relief as well as long-term heart bone and brain heath. Hormone replacement may be either a combined hormonal contraception or with hormone replacement therapy (HRT). The decision is very personal and guided by your specialist.

If you have been diagnosed with POI you be interested in joining the POISE multicentre trial comparing the benefit of different hormone treatments.

Low libido and testosterone replacement

Testosterone may be considered for persistent low sexual desire associated with menopause when HRT alone has not improved symptoms.
In North West London, testosterone treatment for menopause is usually started by a specialist hospital team. Once treatment and the dose are stable, prescribing and monitoring may be continued by your GP according to the local prescribing pathway.

Starting and monitoring testosterone

  • A blood test to measure your testosterone level is required before starting treatment.
  • Your testosterone level will be monitored during treatment to ensure it remains within the female physiological range.
  • Treatment is assessed mainly by whether your symptoms improve and whether you develop side-effects.
  • If side-effects occur, reducing the dose or frequency may help.
  • Treatment should usually be stopped if there has been no meaningful improvement after 3–6 months.

Testosterone preparations

The usual female dose of testosterone is approximately 5 mg per day. As testosterone products contain different concentrations, the amount and frequency used varies between products, but each regimen aims to provide an average dose of around 5 mg per day.
Examples include:
  • Testogel 40.5 mg/2.5 g sachet: approximately one-eighth of a sachet each day.
  • Tostran 2% gel: one measured pump (10 mg), usually applied on alternate days.
  • AndroFeme 1% cream: 0.5 mL (5 mg) applied once daily. This is formulated specifically for women but is not routinely available on the NHS and may require private or specialist prescribing.
The dose may be adjusted according to symptoms, side-effects and blood testosterone levels.

Applying testosterone

Apply the prescribed amount to clean, dry skin, usually on the lower abdomen or outer thigh. Rotate the application site to reduce the risk of increased hair growth in one area.

Possible side-effects

Side-effects are uncommon when testosterone levels remain within the normal female range, but can include:
  • Increased facial or body hair
  • Acne or oily skin
  • Hair thinning
  • Weight gain
  • Voice deepening

Genitourinary symptoms of the menopause (GSM)

Genitourinary syndrome of menopause (GSM) is caused by lower oestrogen levels and can affect the vulva, vagina, bladder and urinary tract. Symptoms can include vaginal or vulval dryness, soreness, itching or burning, pain during sex, urinary symptoms and recurrent urinary tract infections.

When to seek medical advice

Please speak to your GP if your symptoms are severe, persistent, affecting your daily life, or are not improving with treatment. You should also seek medical advice if you have unexplained vaginal bleeding, bleeding after sex or unusual vaginal discharge.
If you have a new sexual partner, are concerned about a sexually transmitted infection (STI), or develop symptoms such as unusual discharge, pain when passing urine, genital sores or blisters, itching, unusual bleeding or pain during sex, please contact a sexual health clinic. Many STIs do not cause symptoms, so testing may still be appropriate if you have a new partner or are concerned about an exposure.

Treatments for GSM

There are several effective treatments. You may need to try more than one option, and treatments can be used together.
Vaginal moisturisers and lubricants
  • Vaginal moisturisers can be used regularly to help improve dryness and discomfort. Examples include Hyalofemme, YES VM and Replens.
  • Lubricants can be used during sex to reduce friction and discomfort. Examples include YES WB and Sylk.
  • Oil-based products may damage latex condoms and other latex barrier contraception.
  • Avoid perfumed soaps, washes and vaginal douches, as these can cause irritation. A soap-free emollient may be more comfortable for washing the vulval area.

Vaginal oestrogen

Low-dose vaginal oestrogen can be used to treat vaginal and vulval dryness, soreness and other symptoms of GSM. It may be used on its own or alongside systemic HRT.
Options include:
  • Estradiol vaginal tablets or pessaries, including Gina, which is available from pharmacies without a prescription for eligible women.
  • Estriol vaginal cream or gel.
  • Other vaginal oestrogen preparations may be prescribed depending on individual needs and availability.
Treatment may need to be continued long term, as symptoms can return when treatment is stopped.

Other treatment options

If symptoms continue despite vaginal oestrogen and non-hormonal treatments, other options may be considered following clinical review:
  • Prasterone (Intrarosa) may be considered for vaginal atrophy and pain during sex where appropriate.
  • Ospemifene (Senshio) may be considered for moderate to severe vulval and vaginal symptoms where appropriate.
  • Pelvic health physiotherapy may help with pain during sex, pelvic floor problems or associated bladder symptoms.
  • Referral to a specialist vulval or dermatology clinic may be appropriate if persistent vulval symptoms do not improve or the diagnosis is uncertain.
Improtant: Availability of some treatments may depend upon your local NHS formulary.

Hormone implant clinic

Before booking your next hormone implant appointment

If you are receiving hormone implants, please make sure you are familiar with the treatment plan outlined in your most recent clinical letter. Please use the following criteria to decide when to book or attend your next implant appointment. You should only request an appointment once all of the criteria below are met, unless a different plan has been agreed with your clinician:
  • Your serum oestradiol level is below 600 pmol/L, or below the individual threshold agreed in your clinical plan.
  • Your menopause symptoms have returned.
  • At least 6 months have passed since your last implant.
Estrogen treatment is prescribed to relieve menopause symptoms. Because implants release hormone over a prolonged period, the timing of your next implant will vary and cannot always be predicted. Your next implant should therefore be guided by your symptoms, blood results and the treatment plan agreed with your clinician, rather than by a fixed schedule.
Important: Having implants too frequently may lead to tachyphylaxis, where progressively higher hormone levels are needed to achieve the same symptom relief. This can result in unnecessarily high hormone levels and make future treatment more difficult to manage.

Wound infection and implant rejection

Any procedure that breaks the skin carries a small risk of infection. Some mild redness, swelling, warmth and discomfort can be normal during the early stages of wound healing. However, you should seek medical advice if these symptoms are increasing rather than improving.
Signs of a possible wound infection include:
  • Increasing or spreading redness, swelling or warmth around the wound
  • Pain or tenderness that is getting worse
  • Yellow or green discharge or pus from the wound
  • The wound opening or not healing as expected
  • Fever or feeling generally unwell
If you develop any of these symptoms, please contact your GP or the clinical team promptly. If you need urgent advice and cannot contact your usual healthcare team, contact NHS 111. If you are seriously unwell, attend A&E or call 999.
Implant rejection
There is a small risk that an implant may be rejected and start to come out through the skin. This is more commonly associated with testosterone implants than oestrogen implants.
Signs may include increasing pain, redness or warmth at the implant site, the wound opening, or the implant becoming visible or coming out.
If this happens, keep the area clean and covered with a sterile dressing and contact the clinical team for advice. Simple pain relief, such as paracetamol, may be taken if it is normally safe for you to do so.

Implant shortages: Estrogen implants are unlicensed in the UK and imported from the United States. The manufacturer has stopped producing these implants, and previous estimates suggested that supplies for existing patients in England would last until April 2026. Future availability remains uncertain. If implants are no longer available, we will discuss suitable alternative treatment options with patients on an individual basis.

Progestogen options in combined HRT 

Sequential progestogen regimens

  1. Micronised progesterone 200 mg: 200 mg taken orally at night for 12 consecutive nights each month.
  2. Micronised progesterone 200 mg vaginally: 200 mg inserted vaginally at night for 12 consecutive nights each month. Off-label route.
  3. Dydrogesterone 10 mg: 10 mg taken orally once daily for 12–14 consecutive days each month.
  4. Norethisterone 5 mg: 5 mg taken orally once daily for 10–12 consecutive days each month. Stand-alone use as part of HRT is off-label.
  5. Medroxyprogesterone acetate (Provera) 10 mg: 10 mg taken orally once daily for 10–12 consecutive days each month.
  6. 52 mg levonorgestrel intrauterine system: Provides continuous endometrial protection alongside oestrogen. Duration of use for endometrial protection should follow current product licensing and clinical guidance.
Specialist progesterone regimens: Crinone 8% vaginal gel, Cyclogest pessaries and Utrogestan 200 mg vaginal pessaries may be considered for endometrial protection as part of sequential HRT in selected patients. Their use for this indication is off-label and evidence is limited. The preparation, dose, frequency and number of treatment days each month are agreed on a patient-by-patient basis following specialist review, taking account of the oestrogen dose, bleeding pattern, tolerability and individual clinical circumstances.
Important: The progestogen dose should be proportionate to the oestrogen dose. Patients using higher-dose oestrogen may require increased progestogen exposure to provide adequate endometrial protection.

Continuous progestogen regimens

  1. Micronised progesterone 100 mg capsule: 100 mg taken orally every night.
  2. Micronised progesterone 100 mg capsule vaginally: 100 mg inserted vaginally every night. Off-label route.
  3. Lutigest 100 mg pessary: 100 mg inserted vaginally every night. Off-label for endometrial protection as part of HRT.
  4. Dydrogesterone 5 mg: 5 mg taken orally every day.
  5. Norethisterone 5 mg: 5 mg taken orally every day. Stand-alone use as part of HRT is off-label.
  6. Medroxyprogesterone acetate (Provera) 5 mg: 5 mg taken orally every day.
  7. 52 mg levonorgestrel intrauterine system: Provides continuous endometrial protection as part of HRT. Duration of use for endometrial protection should follow current product licensing and clinical guidance.
Specialist progesterone regimens: Crinone 8% vaginal gel and Cyclogest pessaries may be considered for endometrial protection as part of continuous HRT in selected patients. Their use for this indication is off-label and evidence is limited. The preparation, dose and frequency are agreed on a patient-by-patient basis following specialist review, taking account of the oestrogen dose, bleeding pattern, tolerability and individual clinical circumstances.
Important: The progestogen dose should be proportionate to the oestrogen dose. Patients using higher-dose oestrogen may require increased progestogen exposure to provide adequate endometrial protection.